BioAtla Crecimiento futuro

Future controles de criterios 0/6

Se prevé un crecimiento anual de los beneficios y los ingresos de BioAtla de 1.7% y 77.7% respectivamente, mientras que el BPA crecerá en un 19.5% al año.

Información clave

3.0%

Tasa de crecimiento de los beneficios

20.9%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	28.5%
Tasa de crecimiento de los ingresos	76.9%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	23 Sep 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

NasdaqGM:BCAB - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	5	-118	-134	N/A	4
12/31/2025	N/A	-103	-127	N/A	4
12/31/2024	N/A	-84	-76	N/A	4
6/30/2024	N/A	-105	-107	-107	N/A
3/31/2024	N/A	-119	-112	-112	N/A
12/31/2023	N/A	-123	-104	-104	N/A
9/30/2023	N/A	-124	-99	-98	N/A
6/30/2023	N/A	-117	-95	-95	N/A
3/31/2023	N/A	-110	-88	-88	N/A
12/31/2022	N/A	-106	-91	-90	N/A
9/30/2022	N/A	-102	-87	-87	N/A
6/30/2022	N/A	-99	-76	-76	N/A
3/31/2022	0	-101	-73	-72	N/A
12/31/2021	0	-95	-63	-62	N/A
9/30/2021	0	-79	-57	-55	N/A
6/30/2021	0	-68	-59	-58	N/A
3/31/2021	0	-44	-49	-48	N/A
12/31/2020	0	-27	-37	-36	N/A
9/30/2020	3	-22	-25	-24	N/A
12/31/2019	5	-29	-11	-10	N/A
12/31/2018	11	-28	-36	-35	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que BCAB siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que BCAB siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que BCAB siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que BCAB no tenga ingresos el año que viene.

Ingresos de alto crecimiento: Se prevé que BCAB no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de BCAB se prevé que sea elevada dentro de 3 años.

BioAtla Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 9.4% to US$15.25

Consensus EPS estimates fall by 13%

Price target decreased by 8.2% to US$24.00

Price target decreased by 8.5% to US$24.71

Price target decreased to US$27.00

Price target decreased to US$41.17

Recent updates

Bioatla, Inc. Presents Promising Phase 2 Trial Data for Ozuriftamab Vedotin At Esmo Annual Meeting, Highlighting Efficacy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

BioAtla, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Bioatla Granted FDA Fast Track Designation for Ozuriftamab Vedotin (CAB-ROR2-ADC) for Treatment of Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

We're A Little Worried About BioAtla's (NASDAQ:BCAB) Cash Burn Rate

BioAtla, Inc.(NasdaqGM:BCAB) dropped from Russell Small Cap Comp Value Index

BioAtla, Inc. Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

New major risk - Financial position

BioAtla, Inc. to Report Q1, 2024 Results on May 14, 2024

BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors

BioAtla: A Buried ADC Concern Gets Some New Life In 2024

BioAtla, Inc., Annual General Meeting, Jun 13, 2024

BioAtla, Inc. to Report Q4, 2023 Results on Mar 26, 2024

New minor risk - Shareholder dilution

Will BioAtla (NASDAQ:BCAB) Spend Its Cash Wisely?

Upendar Golla Files Putative Class Action Lawsuit against Bioatla, Inc

Upendar Golla Files Putative Class Action Lawsuit against Bioatla, Inc

Co-Founder recently bought US$107k worth of stock

Bioatla Hosting Virtual R&D Day to Highlight Ba3071 Cab-Ctla-4 Phase 1 Data in Multiple Solid Tumor Types

BioAtla, Inc. Presents Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event

Is BioAtla (NASDAQ:BCAB) In A Good Position To Deliver On Growth Plans?

BioAtla, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New minor risk - Share price stability

Price target decreased by 9.4% to US$15.25

Consensus EPS estimates fall by 13%

BioAtla, Inc. to Report Q2, 2023 Results on Aug 01, 2023

We Think BioAtla (NASDAQ:BCAB) Needs To Drive Business Growth Carefully

BioAtla, Inc. to Report Q1, 2023 Results on May 11, 2023

Co-Founder recently bought US$101k worth of stock

Price target decreased by 8.2% to US$24.00

Price target decreased by 8.5% to US$24.71

Will BioAtla (NASDAQ:BCAB) Spend Its Cash Wisely?

High number of new and inexperienced directors

BioAtla (NASDAQ:BCAB) Is In A Good Position To Deliver On Growth Plans

BioAtla: Back From The Dead

Price target decreased to US$27.00

BioAtla: Promising Signal In NSCLC, But Concerns Remain

Co-Founder recently bought US$207k worth of stock

BioAtla reports Q2 results

BioAtla, Inc. to Report Q2, 2022 Results on Aug 09, 2022

BioAtla, Inc.(NasdaqGM:BCAB) dropped from Russell 2000 Growth Index

VP of Finance recently bought US$151k worth of stock

Bioatla, Inc. Announces Executive Changes, Effective June 16, 2022

We're Keeping An Eye On BioAtla's (NASDAQ:BCAB) Cash Burn Rate

Price target decreased to US$41.17

High number of new directors

BioAtla, Inc., Annual General Meeting, Jun 16, 2022

BioAtla, Inc. to Report Q1, 2022 Results on May 04, 2022

Consensus forecasts updated

Price target decreased to US$44.40

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$59.60

Companies Like BioAtla (NASDAQ:BCAB) Are In A Position To Invest In Growth

Chief Financial Officer recently sold US$333k worth of stock

Co-Founder notifies of intention to sell stock

Co-Founder recently sold US$1.2m worth of stock

Co-Founder notifies of intention to sell stock

Third quarter 2021 earnings released: US$0.65 loss per share (vs US$1.87 loss in 3Q 2020)

Independent Director notifies of intention to sell stock

President & Director recently sold US$90k worth of stock

President & Director recently sold US$1.3m worth of stock

Independent Director notifies of intention to sell stock

Consensus revenue estimates fall to US$17.6m

BioAtla (NASDAQ:BCAB) Is In A Good Position To Deliver On Growth Plans

BioAtla, Inc.(NasdaqGM:BCAB) dropped from Russell 3000E Value Index

Co-Founder recently sold US$5.0m worth of stock

Are Insiders Buying BioAtla, Inc. (NASDAQ:BCAB) Stock?

BioAtla Conditionally Active Biologic Antibody Design And Functionality For Cancer Treatment Described In Leading Scientific Journal Peer-Reviewed Paper

BioAtla, Inc. has completed an IPO in the amount of $189 million.